Cabotegravir
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Cabotegravir: From HIV-1 Infection to Rheumatoid Arthritis
One-Sentence Summary
Cabotegravir is an HIV-1 integrase strand transfer inhibitor marketed in Canada under several brand names (APRETUDE, VOCABRIA, CABENUVA). The TxGNN model predicts it may be effective for rheumatoid arthritis, but there are currently no clinical trials and no publications supporting this prediction. It rests on a model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Canadian licence data compiled for this report (cabotegravir is known as an HIV-1 integrase inhibitor) |
| Predicted New Indication | Rheumatoid arthritis |
| TxGNN Prediction Score | 0.9945 |
| Evidence Level | L5 (model prediction only) |
| Canada Market Status | Marketed (marketed DINs: 5 of 5) |
| Number of DINs | 5 (marketed: 5) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Cabotegravir is generally known as an HIV-1 integrase strand transfer inhibitor, and its activity is specific to the viral integrase enzyme.
No established mechanism links cabotegravir to rheumatoid arthritis or to immune and inflammatory pathways. The high TxGNN score reflects a TxGNN model (deep learning) prediction only, so any biological connection is speculative and unsupported by trials or literature.
Other top-ranked predictions are similarly weakly supported: sclerosing cholangitis (0.9922), bronchitis (0.9919), colobomatous microphthalmia-rhizomelic dysplasia syndrome (0.9916) and severe nonproliferative diabetic retinopathy (0.9903). All are L5 with no trials or literature. These scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02547473 | APRETUDE | Not listed | Not listed |
| 02497204 | VOCABRIA | Not listed | Not listed |
| 02547465 | APRETUDE | Not listed | Not listed |
| 02497247 | CABENUVA | Not listed | Not listed |
| 02497220 | CABENUVA | Not listed | Not listed |
All five licences are valid authorizations; none are cancelled.
Safety Considerations
Drug Interactions (7 moderate-level interactions identified, all with polyvalent-cation antacids or buffering agents):
- Calcium carbonate
- Aluminum hydroxide
- Magnesium carbonate
- Magnesium hydroxide
- Magnesium oxide
- Sodium bicarbonate
- Sodium citrate
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a TxGNN score, with no clinical trials, no literature, and no plausible mechanistic link between an HIV integrase inhibitor and rheumatoid arthritis. Safety information from the package insert is also not yet available.
To proceed, the following is needed:
- Mechanism of action data (DrugBank) and a credible hypothesis linking integrase inhibition to rheumatoid arthritis pathways
- Health Canada package insert warnings and contraindications
- Approved indication text and dosage form details for the Canadian licences
- Preclinical or early clinical evidence in rheumatoid arthritis
- Route and formulation compatibility assessment (cabotegravir is available in oral and long-acting injectable products, which would need to fit the new indication)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.